'Easily available medicines effective in treating Scleroderma'

Image
Press Trust of India Kochi
Last Updated : Aug 11 2016 | 8:48 PM IST
Two easily available medicines can effectively treat scleroderma interstitial lung disease, a study conducted by an Indian doctor has found.
The research by Kochi-based doctor Padmanabha D Shenoy says data is there to suggest Cyclophosphamide (CYC) and Mycophenolate Mofetil (MMF) are effective in management of scleroderma interstitial lung disease (SSc-ILD).
The study, published in the latest issue of international medical journal 'Arthritis Research and Therapy' is expected to give relief to lakhs of people who suffer from Scleroderma-- a systemic autoimmune disease characterised mainly by skin manifestations and involvement of various visceral organs, especially the lungs, Shenoy said here.
"Approximately 80 per cent of patients have evidence of pulmonary fibrosis at post-mortem examination or on high esolution computed tomography, although clinically evident disease is present only in approximately 40 per cent of patients," it said.
The research said that for over 15 years, cyclophosphamide (CYC) has been used in treating SSc-ILD.
"CYC is a cytotoxic immunosuppressive agent that suppresses lymphokine production and modulates lymphocyte function by alkylating various cellular constituents and depressing the inflammatory response via normalisation of neutrophilia and healing of vascular endothelial cells.
"CYC is the only agent shown to at least stabilise lung function in a randomized, controlled trial," it said.
According to the research, Mycophenolic acid has emerged recently as a promising therapy for SSc.
"Evidence supporting its use derives from small, uncontrolled, single-arm studies, suggesting that mycophenolate is a safe therapeutic modality associated with functional stabilisation of SSc-ILD," the paper said.
"We support the use of immunosuppressants in patients with scleroderma ILD. Although MMF and CYC may be equally effective, MMF may be preferred due to the long-term toxicity of CYC. Larger randomized controlled studies are sorely needed to support this premise," it concludes.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Aug 11 2016 | 8:48 PM IST

Next Story